/ENLV
ENLV Stock - Enlivex Therapeutics Ltd.
Healthcare|BiotechnologyNASDAQ
$0.83+0.40%
+$0.00 (+0.40%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.60
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1696.6%upside
Target: $15.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENLV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.83 – $0.84
TARGET (TP)$15.00
STOP LOSS$0.77
RISK/REWARD1:218.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.49
52W High$2.10
52W Low$0.79
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $2.28M |
| Gross Profit | $-545,000 | $-835,000 | $-777,000 | $-546,000 | $-286,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -12.6% |
| Operating Income | $-15,536,000 | $-29,395,000 | $-25,797,000 | $-19,288,000 | $-9,785,000 |
| Net Income | $-15,014,000 | $-29,068,000 | $-31,060,000 | $-14,468,000 | $-11,824,000 |
| Net Margin | N/A | N/A | N/A | N/A | -519.3% |
| EPS | $-0.73 | $-1.56 | $-2.31 | $-0.54 | $-1.05 |
Company Overview
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ENLVBeat Rate
63%
Last 19 quarters
Avg Surprise
+3.4%
EPS vs Estimate
Beats / Misses
12/6
1 met exactly
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
-71.4%
$-0.48vs$-0.28
Q2 24
+12.0%
$-0.22vs$-0.25
Q3 24
+27.3%
$-0.16vs$-0.22
Q4 24
+25.0%
$-0.12vs$-0.16
Q1 25
-47.8%
$-0.24vs$-0.16
Q2 25
+6.3%
$-0.15vs$-0.16
Q3 25
+50.0%
$-0.08vs$-0.16
Q4 25
+25.0%
$-0.09vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.12 | $-0.09 | +25.0% | ✓ BEAT |
Q3 2025 | Aug 29, 2025 | $-0.16 | $-0.08 | +50.0% | ✓ BEAT |
Q2 2025 | May 30, 2025 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.16 | $-0.24 | -47.8% | ✗ MISS |
Q4 2024 | Nov 29, 2024 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q3 2024 | Aug 30, 2024 | $-0.22 | $-0.16 | +27.3% | ✓ BEAT |
Q2 2024 | Jun 14, 2024 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | $-0.28 | $-0.48 | -71.4% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.32 | $-0.32 | 0.0% | = MET |
Q3 2023 | Sep 1, 2023 | $-0.43 | $-0.37 | +14.0% | ✓ BEAT |
Q2 2023 | Apr 4, 2023 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.38 | $-0.39 | -2.6% | ✗ MISS |
Q4 2022 | Dec 5, 2022 | $-0.29 | $-0.31 | -6.9% | ✗ MISS |
Q3 2022 | Aug 22, 2022 | $-0.45 | $-0.54 | -20.0% | ✗ MISS |
Q2 2022 | May 27, 2022 | $-0.41 | $-0.45 | -9.8% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q4 2021 | Nov 22, 2021 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.26 | $-0.17 | +34.6% | ✓ BEAT |
Q2 2021 | Jun 1, 2021 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Latest News
Enlivex Closes $212M Private Investment, Adopts RAIN Token Treasury Strategy And Advances Allocetra Knee Osteoarthritis Program
📈 PositiveBenzinga•Nov 26, 2025, 01:06 PM
D. Boral Capital Downgrades Enlivex Therapeutics to Hold
📉 NegativeBenzinga•Nov 24, 2025, 03:41 PM
Enlivex Therapeutics shares are trading higher after the company announced a $212M private placement to begin a prediction-market digital assets treasury strategy via Rain token accumulation.
📈 PositiveBenzinga•Nov 24, 2025, 12:56 PM
EXCLUSIVE: Enlivex Therapeutics Tells Benzinga 'Enlivex to continue clinical development of Allocetra TM, a potentially game-changing knee osteoarthritis therapeutic, a growing market with significant unmet medical need'
📈 PositiveBenzinga•Nov 24, 2025, 12:45 PM
EXCUSIVE: Enlivex Therapeutics Tells Benzinga 'Price per share of $1.00, representing a premium of 11.5% from previous closing price'
📈 PositiveBenzinga•Nov 24, 2025, 12:45 PM
EXCUSIVE: Enlivex Therapeutics Tells Benzinga Co. Announces $212M Private Placement To Initiate World's First Prediction market Digital Assets Treasury Strategy Via Rain Token Accumulation, Says 'Co Appoints Matteo Renzi Former Prime Minister Of Italy To Its Board
📈 PositiveBenzinga•Nov 24, 2025, 12:45 PM
Enlivex stock gains on upbeat 6-month results in knee osteoarthritis trial
📈 PositiveSeeking Alpha•Nov 24, 2025, 11:54 AM
Enlivex Therapeutics Ltd. Announces Six-Month Efficacy Data From Phase IIa Allocetra Trial in Knee Osteoarthritis Patients Aged 60+
📈 PositiveBenzinga•Nov 24, 2025, 11:43 AM
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
📈 PositiveBenzinga•Oct 29, 2025, 11:03 AM
Enlivex Therapeutics To Present Late-breaking Poster At ACR Convergence 2025 Featuring Phase IIa Topline Data For Allocetra In Patients With Moderate-To-Severe Knee Osteoarthritis. Data Showed Clinically Meaningful And Statistically Significant Improvements In Pain Reduction And Function Versus Placebo
📈 PositiveBenzinga•Oct 28, 2025, 12:19 PM
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
📈 PositiveBenzinga•Sep 26, 2025, 11:29 AM
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
📈 PositiveBenzinga•Sep 12, 2025, 12:00 PM
Enlivex CEO Oren Hershkovitz Issues Shareholder Letter Highliting Phase IIa Topline Results For Allocetra In Knee Osteoarthritis And Clinical Development Roadmap
📈 PositiveBenzinga•Sep 11, 2025, 12:11 PM
Enlivex Secures Israeli Patent For Allocetra In Osteoarthritis Treatment, Extending IP Protection Through 2040
📈 PositiveBenzinga•Sep 9, 2025, 12:03 PM
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $7 Price Target
📈 PositiveBenzinga•Sep 2, 2025, 11:16 AM
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
📈 PositiveBenzinga•Aug 22, 2025, 11:03 AM
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 12:43 PM
Trading Halt: Halt status updated at 8:00:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 18, 2025, 12:00 PM
Enlivex Drug Shows Relief in Knee Osteoarthritis Trial, Cutting Pain by 72% for Some Patients
📈 PositiveBenzinga•Aug 18, 2025, 11:47 AM
Trading Halt: Halted at 7:40:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 18, 2025, 11:40 AM
Frequently Asked Questions about ENLV
What is ENLV's current stock price?
Enlivex Therapeutics Ltd. (ENLV) is currently trading at $0.83 per share. The stock has moved +0.40% today.
What is the analyst price target for ENLV?
The average analyst price target for ENLV is $15.00, based on 1 analyst.
What sector is Enlivex Therapeutics Ltd. in?
Enlivex Therapeutics Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ENLV's market cap?
Enlivex Therapeutics Ltd. has a market capitalization of $0.02 billion, making it a small-cap company.
Does ENLV pay dividends?
No, Enlivex Therapeutics Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
GDTC
CytoMed Therapeutics Limited
$1.41
Mkt Cap: $0.0B
LSTA
Lisata Therapeutics, Inc.
$2.06
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
NCNA
NuCana plc
$3.56
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
PASG
Passage Bio, Inc.
$9.59
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to ENLV for comparison